First National Bank of Omaha Buys 22,246 Shares of Amgen Inc. $AMGN

First National Bank of Omaha grew its stake in Amgen Inc. (NASDAQ:AMGN) by 54.5% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 63,082 shares of the medical research company’s stock after acquiring an additional 22,246 shares during the quarter. First National Bank of Omaha’s holdings in Amgen were worth $20,683,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in AMGN. Robeco Institutional Asset Management B.V. lifted its holdings in shares of Amgen by 10.0% during the fourth quarter. Robeco Institutional Asset Management B.V. now owns 481,453 shares of the medical research company’s stock valued at $157,584,000 after purchasing an additional 43,884 shares in the last quarter. Curtis Advisory Group LLC bought a new position in shares of Amgen during the fourth quarter valued at $1,669,000. Adell Harriman & Carpenter Inc. lifted its holdings in shares of Amgen by 7.9% during the fourth quarter. Adell Harriman & Carpenter Inc. now owns 22,008 shares of the medical research company’s stock valued at $7,204,000 after purchasing an additional 1,609 shares in the last quarter. Fideuram Intesa Sanpaolo Private Banking S.P.A. bought a new position in shares of Amgen during the fourth quarter valued at $22,441,000. Finally, Sigma Planning Corp lifted its holdings in shares of Amgen by 24.0% during the fourth quarter. Sigma Planning Corp now owns 17,992 shares of the medical research company’s stock valued at $5,889,000 after purchasing an additional 3,488 shares in the last quarter. 76.50% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other Amgen news, SVP Nancy A. Grygiel sold 1,237 shares of the stock in a transaction dated Monday, May 4th. The stock was sold at an average price of $323.73, for a total value of $400,454.01. Following the transaction, the senior vice president owned 7,009 shares of the company’s stock, valued at approximately $2,269,023.57. This represents a 15.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 0.85% of the company’s stock.

Key Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen said its phase 3 ABP 938 eye-disease study is advancing, with the drug aimed at challenging Regeneron’s Eylea HD in a major retina market. That keeps Amgen’s pipeline in focus as a potential future growth driver. Article Title
• Positive Sentiment: Amgen also highlighted its MARITIME-SWITCH phase 3 obesity trial, which is designed to capture GLP-1 switchers. Any success in obesity treatment could open another large market and improve long-term revenue expectations. Article Title
• Positive Sentiment: Some coverage pointed to Amgen as a value stock with supportive new data from the VESALIUS-CV cardiovascular study for Repatha, reinforcing confidence in the company’s broader portfolio. Article Title
• Neutral Sentiment: Amgen and outside analysts published bullish commentary on the stock’s valuation and earnings profile, but these were mostly opinion pieces rather than new business developments. Article Title
• Negative Sentiment: Investor sentiment is being pressured by reports that Amgen’s Tavneos faces a proposed FDA withdrawal, with the company seeking a hearing and commissioning an independent review to defend the drug’s data. Regulatory uncertainty around a $500 million product is a meaningful risk for the stock. Article Title
• Negative Sentiment: Reuters also reported that Amgen hired a research firm to reassess Tavneos data after FDA concerns, underscoring the regulatory overhang and near-term uncertainty for the drug. Article Title

Amgen Stock Up 0.3%

AMGN stock opened at $355.20 on Friday. Amgen Inc. has a fifty-two week low of $267.83 and a fifty-two week high of $391.29. The business’s 50-day moving average is $340.97 and its two-hundred day moving average is $345.72. The company has a debt-to-equity ratio of 5.65, a quick ratio of 1.01 and a current ratio of 1.26. The company has a market cap of $191.70 billion, a price-to-earnings ratio of 24.72, a P/E/G ratio of 3.55 and a beta of 0.42.

Amgen (NASDAQ:AMGN) last posted its earnings results on Thursday, April 30th. The medical research company reported $5.15 earnings per share for the quarter, beating analysts’ consensus estimates of $4.77 by $0.38. Amgen had a return on equity of 137.41% and a net margin of 20.96%.The company had revenue of $8.62 billion for the quarter, compared to the consensus estimate of $8.58 billion. During the same quarter in the prior year, the company earned $4.90 earnings per share. Amgen’s revenue was up 5.8% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. As a group, analysts forecast that Amgen Inc. will post 22.38 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on the company. Erste Group Bank reaffirmed a “hold” rating on shares of Amgen in a report on Tuesday, May 5th. Argus lowered their price target on Amgen from $400.00 to $375.00 and set a “buy” rating on the stock in a report on Wednesday, May 20th. Rothschild & Co Redburn upped their price target on Amgen from $180.00 to $200.00 and gave the company a “sell” rating in a report on Wednesday, February 18th. The Goldman Sachs Group set a $389.00 price target on Amgen in a report on Friday, June 5th. Finally, Piper Sandler reaffirmed an “overweight” rating on shares of Amgen in a report on Friday. Two analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, fourteen have given a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $354.12.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.